Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in A...

Autores
Rodriguez, Alfredo E.; Rodriguez Granillo, Gaston Alfredo; Antoniucci, David; Mieres, Juan; Fernandez Pereira, Carlos; Rodriguez Granillo, Gaston Alfredo; Santaera, Omar; Rubilar, Bibiana; Palacios, Igor F.; Serruys, Patrick W.
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objectives: The Oral Rapamycin in ARgentina (ORAR) III trial is a randomized study comparing a strategy of oral rapamycin (OR) plus bare-metal stent (BMS) versus a strategy of drug-eluting stents (DES) in patients with de novo coronary lesions. The purpose of this study was to assess the 3 years cost-effectiveness outcome of each strategy. Background: OR after BMS has been associated with reduction of target vessel revascularization (TVR) although its value in long-term efficacy in comparison with DES is unknown. Methods: In three hospitals in Buenos Aires, Argentina, 200 patients were randomized to OR plus BMS (n = 100) or DES (n = 100). Primary objectives were costs and effectiveness. Cost analysis included in-hospital and follow-up costs. Safety was defined as the composite of death, myocardial infarction (MI), and stroke. Efficacy was defined as TVR. Results: Baseline characteristics between groups were similar. The 3-year follow-up rate was 99%. Cardiac mortality was 2% and 5% in OR group and DES group, respectively (P = 0.44). The composite of death, MI and stroke rate was 11% in OR group and 20% in DES group (P = 0.078). TVR rate was 14.5% in OR group and 17.6% in DES group (P = 0.50), respectively. Three year cumulative costs were significantly lower in the OR arm as compared to the DES arm (P = 0.0001) and DES strategy did not result cost-effective according to the non-inferiority test. Conclusions: At 3 years follow-up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost-effective as compared to OR plus BMS.
Fil: Rodriguez, Alfredo E.. Sanatorio "Otamendi y Miroli S. A."; Argentina. Centro de Estudios en Cardiologia Intervencionista; Argentina
Fil: Rodriguez Granillo, Gaston Alfredo. Centro de Estudios en Cardiologia Intervencionista; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Antoniucci, David. Careggi Hospital; Italia
Fil: Mieres, Juan. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Fernandez Pereira, Carlos. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Rodriguez Granillo, Gaston Alfredo. Sanatorio "Otamendi y Miroli S. A."; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Santaera, Omar. Clínica Ima; Argentina
Fil: Rubilar, Bibiana. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Palacios, Igor F.. Colegio Argentino de Cardioangiólogos Intervencionistas; Argentina
Fil: Serruys, Patrick W.. Cardialysis; Países Bajos
Materia
DRUG ELUTING STENTS
CORONARY
RESTENOSIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/240932
Acceder
id CONICETDig_c76762a110c6a7de894f8eec7325a478
oai_identifier_str oai:ri.conicet.gov.ar:11336/240932
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trialRodriguez, Alfredo E.Rodriguez Granillo, Gaston AlfredoAntoniucci, DavidMieres, JuanFernandez Pereira, CarlosRodriguez Granillo, Gaston AlfredoSantaera, OmarRubilar, BibianaPalacios, Igor F.Serruys, Patrick W.DRUG ELUTING STENTSCORONARYRESTENOSIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Objectives: The Oral Rapamycin in ARgentina (ORAR) III trial is a randomized study comparing a strategy of oral rapamycin (OR) plus bare-metal stent (BMS) versus a strategy of drug-eluting stents (DES) in patients with de novo coronary lesions. The purpose of this study was to assess the 3 years cost-effectiveness outcome of each strategy. Background: OR after BMS has been associated with reduction of target vessel revascularization (TVR) although its value in long-term efficacy in comparison with DES is unknown. Methods: In three hospitals in Buenos Aires, Argentina, 200 patients were randomized to OR plus BMS (n = 100) or DES (n = 100). Primary objectives were costs and effectiveness. Cost analysis included in-hospital and follow-up costs. Safety was defined as the composite of death, myocardial infarction (MI), and stroke. Efficacy was defined as TVR. Results: Baseline characteristics between groups were similar. The 3-year follow-up rate was 99%. Cardiac mortality was 2% and 5% in OR group and DES group, respectively (P = 0.44). The composite of death, MI and stroke rate was 11% in OR group and 20% in DES group (P = 0.078). TVR rate was 14.5% in OR group and 17.6% in DES group (P = 0.50), respectively. Three year cumulative costs were significantly lower in the OR arm as compared to the DES arm (P = 0.0001) and DES strategy did not result cost-effective according to the non-inferiority test. Conclusions: At 3 years follow-up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost-effective as compared to OR plus BMS.Fil: Rodriguez, Alfredo E.. Sanatorio "Otamendi y Miroli S. A."; Argentina. Centro de Estudios en Cardiologia Intervencionista; ArgentinaFil: Rodriguez Granillo, Gaston Alfredo. Centro de Estudios en Cardiologia Intervencionista; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Antoniucci, David. Careggi Hospital; ItaliaFil: Mieres, Juan. Sanatorio "Otamendi y Miroli S. A."; ArgentinaFil: Fernandez Pereira, Carlos. Sanatorio "Otamendi y Miroli S. A."; ArgentinaFil: Rodriguez Granillo, Gaston Alfredo. Sanatorio "Otamendi y Miroli S. A."; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Santaera, Omar. Clínica Ima; ArgentinaFil: Rubilar, Bibiana. Sanatorio "Otamendi y Miroli S. A."; ArgentinaFil: Palacios, Igor F.. Colegio Argentino de Cardioangiólogos Intervencionistas; ArgentinaFil: Serruys, Patrick W.. Cardialysis; Países BajosWiley-liss, div John Wiley & Sons Inc.2012-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/mswordapplication/pdfhttp://hdl.handle.net/11336/240932Rodriguez, Alfredo E.; Rodriguez Granillo, Gaston Alfredo; Antoniucci, David; Mieres, Juan; Fernandez Pereira, Carlos; et al.; Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial; Wiley-liss, div John Wiley & Sons Inc.; Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions.; 80; 3; 9-2012; 385-3941522-726X1522-1946CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.23352info:eu-repo/semantics/altIdentifier/doi/10.1002/ccd.23352info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:29Zoai:ri.conicet.gov.ar:11336/240932instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:29.817CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
title Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
spellingShingle Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
Rodriguez, Alfredo E.
DRUG ELUTING STENTS
CORONARY
RESTENOSIS
title_short Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
title_full Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
title_fullStr Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
title_full_unstemmed Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
title_sort Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial
dc.creator.none.fl_str_mv Rodriguez, Alfredo E.
Rodriguez Granillo, Gaston Alfredo
Antoniucci, David
Mieres, Juan
Fernandez Pereira, Carlos
Rodriguez Granillo, Gaston Alfredo
Santaera, Omar
Rubilar, Bibiana
Palacios, Igor F.
Serruys, Patrick W.
author Rodriguez, Alfredo E.
author_facet Rodriguez, Alfredo E.
Rodriguez Granillo, Gaston Alfredo
Antoniucci, David
Mieres, Juan
Fernandez Pereira, Carlos
Santaera, Omar
Rubilar, Bibiana
Palacios, Igor F.
Serruys, Patrick W.
author_role author
author2 Rodriguez Granillo, Gaston Alfredo
Antoniucci, David
Mieres, Juan
Fernandez Pereira, Carlos
Santaera, Omar
Rubilar, Bibiana
Palacios, Igor F.
Serruys, Patrick W.
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv DRUG ELUTING STENTS
CORONARY
RESTENOSIS
topic DRUG ELUTING STENTS
CORONARY
RESTENOSIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objectives: The Oral Rapamycin in ARgentina (ORAR) III trial is a randomized study comparing a strategy of oral rapamycin (OR) plus bare-metal stent (BMS) versus a strategy of drug-eluting stents (DES) in patients with de novo coronary lesions. The purpose of this study was to assess the 3 years cost-effectiveness outcome of each strategy. Background: OR after BMS has been associated with reduction of target vessel revascularization (TVR) although its value in long-term efficacy in comparison with DES is unknown. Methods: In three hospitals in Buenos Aires, Argentina, 200 patients were randomized to OR plus BMS (n = 100) or DES (n = 100). Primary objectives were costs and effectiveness. Cost analysis included in-hospital and follow-up costs. Safety was defined as the composite of death, myocardial infarction (MI), and stroke. Efficacy was defined as TVR. Results: Baseline characteristics between groups were similar. The 3-year follow-up rate was 99%. Cardiac mortality was 2% and 5% in OR group and DES group, respectively (P = 0.44). The composite of death, MI and stroke rate was 11% in OR group and 20% in DES group (P = 0.078). TVR rate was 14.5% in OR group and 17.6% in DES group (P = 0.50), respectively. Three year cumulative costs were significantly lower in the OR arm as compared to the DES arm (P = 0.0001) and DES strategy did not result cost-effective according to the non-inferiority test. Conclusions: At 3 years follow-up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost-effective as compared to OR plus BMS.
Fil: Rodriguez, Alfredo E.. Sanatorio "Otamendi y Miroli S. A."; Argentina. Centro de Estudios en Cardiologia Intervencionista; Argentina
Fil: Rodriguez Granillo, Gaston Alfredo. Centro de Estudios en Cardiologia Intervencionista; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Antoniucci, David. Careggi Hospital; Italia
Fil: Mieres, Juan. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Fernandez Pereira, Carlos. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Rodriguez Granillo, Gaston Alfredo. Sanatorio "Otamendi y Miroli S. A."; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Santaera, Omar. Clínica Ima; Argentina
Fil: Rubilar, Bibiana. Sanatorio "Otamendi y Miroli S. A."; Argentina
Fil: Palacios, Igor F.. Colegio Argentino de Cardioangiólogos Intervencionistas; Argentina
Fil: Serruys, Patrick W.. Cardialysis; Países Bajos
description Objectives: The Oral Rapamycin in ARgentina (ORAR) III trial is a randomized study comparing a strategy of oral rapamycin (OR) plus bare-metal stent (BMS) versus a strategy of drug-eluting stents (DES) in patients with de novo coronary lesions. The purpose of this study was to assess the 3 years cost-effectiveness outcome of each strategy. Background: OR after BMS has been associated with reduction of target vessel revascularization (TVR) although its value in long-term efficacy in comparison with DES is unknown. Methods: In three hospitals in Buenos Aires, Argentina, 200 patients were randomized to OR plus BMS (n = 100) or DES (n = 100). Primary objectives were costs and effectiveness. Cost analysis included in-hospital and follow-up costs. Safety was defined as the composite of death, myocardial infarction (MI), and stroke. Efficacy was defined as TVR. Results: Baseline characteristics between groups were similar. The 3-year follow-up rate was 99%. Cardiac mortality was 2% and 5% in OR group and DES group, respectively (P = 0.44). The composite of death, MI and stroke rate was 11% in OR group and 20% in DES group (P = 0.078). TVR rate was 14.5% in OR group and 17.6% in DES group (P = 0.50), respectively. Three year cumulative costs were significantly lower in the OR arm as compared to the DES arm (P = 0.0001) and DES strategy did not result cost-effective according to the non-inferiority test. Conclusions: At 3 years follow-up, there were no differences in effectiveness between the two strategies, and DES strategy was not more cost-effective as compared to OR plus BMS.
publishDate 2012
dc.date.none.fl_str_mv 2012-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/240932
Rodriguez, Alfredo E.; Rodriguez Granillo, Gaston Alfredo; Antoniucci, David; Mieres, Juan; Fernandez Pereira, Carlos; et al.; Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial; Wiley-liss, div John Wiley & Sons Inc.; Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions.; 80; 3; 9-2012; 385-394
1522-726X
1522-1946
CONICET Digital
CONICET
url http://hdl.handle.net/11336/240932
identifier_str_mv Rodriguez, Alfredo E.; Rodriguez Granillo, Gaston Alfredo; Antoniucci, David; Mieres, Juan; Fernandez Pereira, Carlos; et al.; Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial; Wiley-liss, div John Wiley & Sons Inc.; Catheterization And Cardiovascular Interventions : Official Journal Of The Society For Cardiac Angiography & Interventions.; 80; 3; 9-2012; 385-394
1522-726X
1522-1946
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.23352
info:eu-repo/semantics/altIdentifier/doi/10.1002/ccd.23352
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/msword
application/pdf
dc.publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
publisher.none.fl_str_mv Wiley-liss, div John Wiley & Sons Inc.
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269583012003840
score 13.13397

Publicaciones similares